首页> 外文期刊>Pharmacology, Biochemistry and Behavior >The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.
【24h】

The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.

机译:促肾上腺皮质激素释放因子1受体拮抗剂SSR125543和加压素1b受体拮抗剂SSR149415可以预防小鼠的应激诱导的认知障碍。

获取原文
获取原文并翻译 | 示例
           

摘要

The vasopressin 1b receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, are orally active non-peptidic compounds with anxiolytic- and antidepressant-like activities in animals. In the present study, their effects on stress-induced deficit in cognitive performances as assessed in a modified object recognition test were investigated in mice. The object recognition task measures the ability of a mouse to remember an object it has previously explored in a learning trial. During this acquisition session, the mouse was stressed by the presence of a pair of rats under the grid floor of the apparatus. One hour later, it was placed again in the environment with the known and a novel object, but in the absence of the rats. While non-exposed mice spent more time exploring the new object, mice that had been exposed to the rats during acquisition failed to discriminate between the known and the new object during retrieval. This cognitive impairment in stressed mice was prevented by the administration of SSR149415 (10 mg/kg, ip), SSR125543 (10 mg/kg, ip) and the selective serotonin reuptake inhibitor, fluoxetine (10 mg/kg, ip). Under similar conditions, the cognitive enhancer donepezil (1 mg/kg, ip) failed to reverse object recognition deficit. These results indicate that the effects of SSR149415 and SSR125543 in the modified object recognition test, in stressed mice, involve the ability of mice to cope with stress rather than an effect on cognition per se. Together, these data suggest that SSR149415 and SSR125543 may be of interest to reduce the cognitive deficits following exposure to stress-related events, such as acute stress disorder.
机译:加压素1b受体拮抗剂SSR149415和促肾上腺皮质激素释放因子1受体拮抗剂SSR125543是在动物中具有抗焦虑和抗抑郁样活性的口服活性非肽化合物。在本研究中,在小鼠中研究了它们对应激诱导的认知能力缺陷的影响,如在改进的物体识别测试中评估的那样。对象识别任务测量鼠标记住它先前在学习试验中探索过的对象的能力。在此获取会话期间,鼠标在设备网格地板下的一对老鼠的存在下感到压力。一小时后,将它再次放置在具有已知和新颖物体的环境中,但是没有老鼠。尽管未暴露的老鼠花了更多时间探索新物体,但是在采集过程中暴露于老鼠的老鼠却无法在取回过程中区分已知物体和新物体。服用SSR149415(10 mg / kg,ip),SSR125543(10 mg / kg,ip)和选择性5-羟色胺再摄取抑制剂氟西汀(10 mg / kg,ip)可预防应激小鼠的这种认知障碍。在相似的条件下,认知增强剂多奈哌齐(1 mg / kg,ip)无法逆转物体识别缺陷。这些结果表明,在应激小鼠中,SSR149415和SSR125543在改良的对象识别测试中的作用涉及小鼠应付压力的能力,而不是对认知本身的影响。总之,这些数据表明,SSR149415和SSR125543可能对于减少暴露于应激相关事件(如急性应激障碍)后的认知功能障碍很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号